Charles River Laboratories International, Inc.
$314.32-$13.61 (-4.2%)
Last close · Data as of Nov 20, 2026
- Market cap
- $8.9B
- EV / EBITDA
- 27.5x
- Revenue
- $4.0B
- Net margin
- -3.6%
- ROCE
- 0.1%
Price chart
Technical chartScreen technicals →+93.9% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -0.4%
- 3M
- +7.8%
- 6M
- +101.4%
- 1Y
- +93.9%
- 5Y
- -17.3%
52-week range
Day change -$13.61 (-4.2%) from $328 to $314 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in CRL, bought on each weekday since 2021.
News & filings
What Charles River Laboratories International filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 144 million US dollars in fiscal 2025.
Strengths (1)
- The price is 36.1% above its 200-day average, and the 50-day average is above the 200-day.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
Read moreShow less
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 49.2M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $8.9B
- P/B
- 2.8x
- EV / EBITDA
- 27.5x
- EV / Sales
- 2.8x
- P/S
- 2.2x
- 52-week high
- $376.10
- 52-week low
- $149.93
Profitability
- Operating margin
- 10.0%
- Net margin
- -3.6%
- EBITDA margin
- 10.2%
- ROE
- -4.6%
- ROCE
- 0.1%
- ROA
- -2.0%
- Asset turnover
- 0.56
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $4.0B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -0.9%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 0.3%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -1501.7%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $518.5M
Solvency
- Current ratio
- 1.29
- Debt / Equity
- 0.81
- Debt / Assets
- 0.36
- CFO / Net profit
- -5.11
- Cash / Market cap
- 2.4%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $4.0B |
| Cost of revenue | $2.7B |
| Gross profit | $1.3B |
| Operating expenses | $922.1M |
| Selling, general and administrative | $743.1M |
| Operating income | $401.1M |
| Interest and other | -$500.6M |
| Pretax income | -$99.5M |
| Tax and other | $44.8M |
| Net income | -$144.3M |
Revenue and net profit
Revenue fell 0.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $4.0B | $486.2M |
| FY2023 | $4.1B | $474.6M |
| FY2024 | $4.0B | $10.3M |
| FY2025 | $4.0B | -$144.3M |
Cash flows
FY2025: $737.6M from operations, $518.5M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $619.6M | $294.9M |
| FY2023 | $683.9M | $365.4M |
| FY2024 | $734.6M | $501.6M |
| FY2025 | $737.6M | $518.5M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $4.0B-0.9%1Y
- EBITDA
- $410.8M-29.3%1Y
- Net profit
- -$144.3M-1,501.7%1Y
- Cash from operations
- $737.6M+0.4%1Y
- Free cash flow
- $518.5M+3.4%1Y
- Revenue CAGR, 3Y
- 0.3%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $4.0B | $410.8M | -$144.3M | $518.5M | -4.6% | -0.9% | -1501.7% |
Monthly returns
Month-by-month returns of CRL across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $7.1B |
| Current assets | $1.4B |
| Non-current assets | $5.7B |
| Liabilities | $3.9B |
| Current liabilities | $1.1B |
| Non-current liabilities | $2.8B |
| Equity | $3.2B |
| Paid-in capital | $1.9B |
| Retained earnings | $1.4B |
| Treasury stock | $0.00 |
| Minority interest | $46.6M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; CRL highlighted.
P/E against peers
CRL has no positive P/E; the peer median is 25.9x.
Not shown (no positive earnings and no EV / Sales): Charles River Laboratories International, Inc., Baxter International Inc., Glaukos Corporation.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Charles River Laboratories International, Inc.CRLthis company | $8.9B | — | 2.8x | -4.6% | 27.5x |
| Molina Healthcare, Inc.MOH | $10.0B | 21.3x | 2.5x | 11.6% | — |
| Baxter International Inc.BAX | $10.0B | -10.4x | 1.6x | -15.6% | 23.2x |
| Krystal Biotech, Inc.KRYS | $9.1B | 44.3x | 7.4x | 16.8% | 51.2x |
| Henry Schein, Inc.HSIC | $8.7B | 21.8x | 2.7x | 12.3% | 12.4x |
| Bio-Techne CorporationTECH | $8.3B | 113.5x | 4.3x | 3.8% | 39.7x |
| Corcept Therapeutics IncorporatedCORT | $8.0B | 80.7x | 12.4x | 15.4% | 66.1x |
| Alkermes plcALKS | $7.2B | 29.9x | 4.0x | 13.3% | 20.9x |
| Glaukos CorporationGKOS | $7.1B | -38.1x | 10.9x | -28.6% | -49.0x |
| Peer median | — | 25.9x | 4.2x | 11.9% | 23.2x |
Year-to-date ROI
CRL since 1 January, against earlier years.
Historical volatility
CRL's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 16.4% |
| FY2023 | 14.9% |
| FY2024 | 10.9% |
| FY2025 | 10.0% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $4.0B |
| Cost of revenueCost Of Revenue | $2.7B |
| Gross profitGross Profit | $1.3B |
| Operating expensesOperating Expense | $922.1M |
| Selling, general and administrativeSelling General And Administration | $743.1M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $179.1M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $179.1M |
| Amortization | $179.1M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $179.1M |
| Total expensesTotal Expenses | $3.6B |
| Operating incomeOperating Income | $401.1M |
| Interest and other | |
| Pretax incomePretax Income | -$99.5M |
| TaxTax Provision | $42.7M |
| Net incomeNet Income | -$144.3M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $7.1B |
| Current assetsCurrent Assets | $1.4B |
| Non-current assetsTotal Non Current Assets | $5.7B |
| LiabilitiesTotal Liabilities Net Minority Interest | $3.9B |
| Current liabilitiesCurrent Liabilities | $1.1B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $2.8B |
| EquityTotal Equity Gross Minority Interest | $3.2B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $737.6M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $737.6M |
| Net income, continuing operationsNet Income From Continuing Operations | -$142.2M |
| Depreciation and amortisationDepreciation And Amortization | $403.3M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $403.3M |
| Stock-based compensationStock Based Compensation | $71.1M |
| Deferred taxDeferred Tax | -$75.3M |
| Deferred income taxDeferred Income Tax | -$75.3M |
| Operating gains and lossesOperating Gains Losses | $21.5M |
| Gain loss on sale of businessGain Loss On Sale Of Business | -$3.4M |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | $24.9M |
| Asset impairmentAsset Impairment Charge | $436.5M |
| Provision and write off of assetsProvisionand Write Offof Assets | $6.1M |
| Change in working capitalChange In Working Capital | $14.1M |
| Other non-cash itemsOther Non Cash Items | $2.5M |
| Investing cash flowInvesting Cash Flow | -$209.3M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$209.3M |
| Capital expenditureCapital Expenditure | -$219.2M |
| AcquisitionsPurchase Of Business | $0.00 |
| DisposalsSale Of Business | $17.4M |
| Net acquisitions and disposalsNet Business Purchase And Sale | $17.4M |
| Purchase of investmentsPurchase Of Investment | -$20.1M |
| Sale of investmentsSale Of Investment | $9.1M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$11.0M |
| Other investing changesNet Other Investing Changes | $3.4M |
| Financing cash flowFinancing Cash Flow | -$536.7M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$536.7M |
| Debt issuedIssuance Of Debt | $1.2B |
| Debt repaidRepayment Of Debt | -$1.3B |
| Net debt issuedNet Issuance Payments Of Debt | -$121.8M |
| Long-term debt issuedLong Term Debt Issuance | $1.2B |
| Long-term debt repaidLong Term Debt Payments | -$1.3B |
| Net long-term debt issuedNet Long Term Debt Issuance | -$121.8M |
| Net common stock issuedNet Common Stock Issuance | -$360.7M |
| Common stock repurchasedCommon Stock Payments | -$360.7M |
| Share buybacksRepurchase Of Capital Stock | -$360.7M |
| Stock options exercisedProceeds From Stock Option Exercised | $710.0k |
| Other financing chargesNet Other Financing Charges | -$55.0M |
| Change in cashChanges In Cash | -$8.4M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 1,883.0% |
| Cash at the start of the yearBeginning Cash Position | $205.6M |
| Cash at the end of the yearEnd Cash Position | $216.0M |
| Free cash flowFree Cash Flow | $518.5M |
| Supplemental |
Learn while you research
Academy chapters picked for Charles River Laboratories International, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read